CIENCIASMEDICASNEWS

Navigating Advances in TRK Fusion-Positive Cancers: A Collaborative Journey From Testing to Therapy Authors: David S. Hong, MD; Theodore W. Laetsch, MD; Jonathan C. Trent, MD, PhD

https://www.medscape.org/viewarticle/navigating-advances-trk-fusion-positive-cancers-2025a1000z5i?page=1&src=mkmcmr_driv_stan_mscpedu_260612-OUS-HONC-navigating-advances-trk-fusion-positive-cancers-2025a1000z5i-cta&uac=148436CN

Drug-Induced Alopecia: When to Suspect and How to Treat It Matías A. Loewy

https://www.medscape.com/viewarticle/drug-induced-alopecia-when-suspect-and-how-treat-it-2026a1000jrt Key considerations in the diagnosis and management of drug-induced alopecia include the timing of onset, biologic plausibility, underlying pathophysiologic mechanism, and, in some cases, scalp biopsy findings, according to Jorge Larrondo Gálvez, MD , surgeon and specialist in dermatology and trichology in the Department of Dermatology, Clínica Alemana-Universidad del Desarrollo, Santiago, Chile.

Mesothelioma Survival Challenges Persist in the US Edited by Katie Lennon June 12, 2026

https://www.medscape.com/viewarticle/mesothelioma-survival-challenges-persist-us-2026a1000jsv Mesothelioma incidence and mortality declined more than 30% nationally from 1990 to 2023, with males experiencing reductions exceeding 40% while female rates decreased by < 10%. Female incidence increased in 20 states and mortality in 18, with occupational asbestos exposure accounting for more than 95% of deaths in 2023 and mortality-to-incidence ratios rising from 0.93 to 0.95.

Extrahepatic Cancer Risk Varies by Liver Disease Subgroups Edited by Vinod Rane, BS Pharm

https://www.medscape.com/viewarticle/extrahepatic-cancer-risk-varies-liver-disease-subgroups-2026a1000jlf Among subgroups of steatotic liver disease (SLD), metabolic dysfunction and alcohol-associated liver disease (MetALD) and alcohol-related liver disease (ALD) were associated with a higher risk for extrahepatic cancers than metabolic dysfunction-associated SLD (MASLD).

Chemo-Free Therapy in Pediatric Acute Promyelocytic Leukemia Cristina Ferrario Medscape Europe logo June 12, 2026

https://www.medscape.com/viewarticle/chemo-free-therapy-pediatric-acute-promyelocytic-leukemia-2026a1000jvy STOCKHOLM —Eliminating anthracyclines from the treatment regimen of children and adolescents newly diagnosed with acute promyelocytic leukemia (APL) is feasible and yields excellent positive outcomes in standard-risk and high-risk patients, new data suggest. At the 2026 European Hematology Association Congress, Franco Locatelli presented the final results of the ICC-APL-02 trial, paving the way for a new treatment approach that dispenses with conventional chemotherapy in this pediatric population. European Hematology Association (EHA) 2026 Congress https://www.medscape.com/c25/p14/european-hematology-association-eha-2026-congress-2026a1000g3s

Belzutifan Plus Pembro Approved for Adjuvant RCC M. Alexander Otto, PA, MMSc June 12, 2026

https://www.medscape.com/viewarticle/belzutifan-plus-pembro-approved-adjuvant-rcc-2026a1000jxb The FDA has approved belzutifan (Welireg, Merck) in combination with pembrolizumab (Keytruda, Merck) or the subcutaneous formulation of pembrolizumab (Keytruda Qlex, Merck) for the adjuvant treatment of adults with clear cell renal cell carcinoma.